| Description | SIRT6-IN-3 (compound 8a), a selective SIRT6 inhibitor (IC50 = 7.49 μM), impedes the proliferation of pancreatic ductal adenocarcinoma (PDAC) cells and prompts apoptosis. It enhances the responsiveness of cancer cells to gemcitabine by obstructing the DNA damage repair pathway, thus serving as a valuable tool in pancreatic cancer research [1]. |
| In vitro | SIRT6-IN-3 (25 μM，48小时) 能够诱导PDAC细胞发生细胞周期阻滞与细胞凋亡；同一化合物在72小时内通过抑制相关的细胞信号通路有效抑制胰腺癌细胞的增殖[1]。 |
| In vivo | SIRT6-IN-3在肿瘤小鼠模型中展现了抗肿瘤活性，并且当与吉西他滨以2:1的比例联合使用时，能够增强吉西他滨的抗肿瘤效果[1]。 |
| Target activity | SIRT1:80.52 μM, SIRT2:92.21 μM, SIRT6:7.46 μM, HDAC3:111.9 μM, HDAC6:96.77 μM, HDAC8:102 μM |
| molecular weight | 673.73 |
| Molecular formula | C21H30Br3ClN6S |
| CAS | 3023471-40-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |